Significant Contract Modifications ($10M+) — March 26, 2026

Three contracts totaling $793M (45% of period value) to Westat, PPD, and Advanced Tech provide multi-year visibility through 2029 in tobacco, biotech, and COVID R&D.

AATD's $138M obligated (76% outlayed) SDVOSB set-aside delivery order signals strong VA endpoint IT demand with $285M options upside to 2026.

Acacia's $832M (47% of total) refugee legal contract with 94% outlayed reflects reliable DOI/HHS funding but no equity upside as nonprofit.

Long performance periods (2026-2029) across 80% of value expose to funding shifts, with low early outlays in BARDA awards ($240K vs $161M; $23M vs $126M).

COVID-focused R&D ($126M) vulnerable to shifting pandemic priorities; firm-fixed-price structures risk overruns for AATD ($138M) and Advanced Tech ($161M).

Unexercised options exceed $900M across contracts (e.g., Westat $455M, AATD $285M), with high outlay rates signaling likely exercise.

BARDA biotech/pharma R&D awards ($287M total) indicate follow-on potential in health innovation.

45% of value in health R&D (NAICS 54171x) via NIH/BARDA underscores federal biotech/tobacco/COVID commitment through 2029.

AATD's SDVOSB/8(a) IT win ($138M, 8% of total) highlights VA preferences limiting competition.

{"entity"=>"Westat, Inc.", "reason"=>"$505M PATH Study with $455M options and 42% outlayed offers longest visibility to 2028.", "trigger"=>"outlays >$50M/quarter or option exercise"}

{"entity"=>"PPD Development LP", "reason"=>"$126M COVID R&D fully obligated to 2029 but early-stage (18% outlayed) with pandemic sensitivity.", "trigger"=>"HHS funding cuts or accelerated disbursements"}

{"entity"=>"AATD LLC", "reason"=>"SDVOSB with $285M options upside and 76% outlay progress in VA IT.", "trigger"=>"additional VA delivery orders or set-aside expansions"}